Bazedoxifene, a third-generation SERM with IL-6/GP130 inhibitory effects, markedly potentiated the anti-tumor 5-FU activity in vitro and in vivo, implying a potential role for IL-6 pathway inhibition in reversing chemoresistance [207]. The gene discussed is IL6; the disease is neoplasm.